Navigation Links
VirtualScopics, Inc. Reports Second Quarter and Six Months 2014 Financial Results; Awards Outstanding and Bookings Reflect a Two-Fold Increase Over 2013 First Six Months
Date:8/14/2014

ed services provided by other clinical trial imaging providers.  Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, every day clinical trial imaging services.  For more information about VirtualScopics, Inc. please visit www.virtualscopics.com.

Forward-looking StatementsThe statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby.  These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the company's investment in infrastructure, new office in New Hope, Pennsylvania, the Scientific Advisory Board, the strategic alliance with IXICO plc, the increase in awards outstanding and bookings and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions.  Forward-looking statements deal with the company's current plans, intentions, beliefs and expectations.  Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available
'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman
2. Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc.
3. VirtualScopics, Inc. Schedules Second Quarter 2014 Financial Results Press Release, Conference Call And Webcast
4. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
5. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
6. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
9. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
10. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
11. Luminex Corporation Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that on ... company,s vice president of operations, was granted an option to ... per share exercise price of $0.43, the closing trading price ... to Cardica, Inc.,s Inducement Plan, which was approved by the ... of the Nasdaq Global Market for equity grants to induce ...
(Date:5/21/2015)... -- The Pharmaceutical Care Management Association (PCMA) issued ... offsets included in the Energy & Commerce Committee,s ... 21st Century Cures initiative can only be advanced by ... Medicare – then its costs outweigh any potential ... "Leveraging payments to Part D plans to ...
(Date:5/21/2015)... May 21, 2015 ... - Zwecks Leistungsvergleich zur Expertise und ... EG-Mitgliedstaaten verwiesen, in denen uneingeschränkt betriebsfähige ... Sie ein Aegate-Land: beispielsweise BELGIEN   ... Bekämpfung von Arzneimittelfälschungen (FMD) handelt es ...
Breaking Medicine Technology:Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its ... $175 million in unlawful profits from the sale of products that were ... , , ... , , ...
... ExpertRECALL, the leader in the field of recall logistics and ... recall logistics management in the food, drug and consumer products industries to ... with Michaels Stores, Inc. , ... Upon completion of their studies at Saint Louis University ,s ...
Cached Medicine Technology:Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3ExpertRECALL Awards First Scholarships for Product-Safety Education 2
(Date:5/24/2015)... 2015 EnviroLeather™ by LDI, a ... – a classic, rugged leather grain with enhanced ... stains, including ink, to be easily removed. The ... for corporate, healthcare, hospitality and education environments. , ... goal of developing products that are more sustainable, ...
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the leading ... America, Inc. (MTA) has selected IFN as a fiber ... Enterprise Sales Manager, fiber route diversity and network redundancy ... provides MTA with the diverse fiber transport from their ... and voice carriers located at Henry Street in Indianapolis, ...
(Date:5/24/2015)... A report out just last ... best option for avoiding cardiovascular disease is exercise and ... the single most powerful predictor of death and survival, ... and family history of premature death -- a finding ... lung fitness. , The Importance of Cardiovascular Screening , ...
(Date:5/23/2015)... 23, 2015 Dr. David Benvenuti, an experienced ... posted a new article to his website that ... Dr Benvenuti explained in the fascinating blog, he has ... their earlobes. , Known as “gauging,” the technique involves placing ... Dr. Benvenuti said will eventually stretch the holes out to ...
(Date:5/23/2015)... On May 16, the team at Farrell’s eXtreme ... mud obstacle run that raised funds for multiple sclerosis. ... the reason we participated was to support people living with ... eXtreme Bodyshaping. “One-hundred percent of the funds raised go to ... not only attended by eXtreme Bodyshaping staff, but members of ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... , , BATESVILLE, ... and Radianse today announced a strategic partnership agreement to integrate ... Nurse Call system. With this move, Hill-Rom intends to ... to remove financial and technical obstacles for health care customers ...
... , VIENNA, Va., Sept. 2 ... ), a developer of vaccines for the prevention and treatment of ... of Series K convertible notes (the "Notes"). The Notes, which ... August 2006, and were convertible into common stock. , , ...
... ... (SIAC) will host Measuring Study Endpoints in Multinational Clinical Trials: Outcomes Reported from the ... LA. , ... Horsham, PA (Vocus) September 2, 2009 --The Drug Information Association (DIA) Study ...
... , SOMERSET, N.J., Sept. 2 ... and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal ... and perennial allergic rhinitis (SAR and PAR). New ASTEPRO ... convenient once-daily dosing for patients who suffer from seasonal allergies. ...
... , PARSIPPANY, N.J., Sept. 2 The following is ... Communication about the safety review of orlistat: , , ... safety review of orlistat and liver-related serious adverse events. , , ... http://www.prnewswire.com/mnr/alli/39949/ , , It,s important consumers know ...
... , , TUCSON, Ariz., Sept. 2 ... Fletcher McCusker, Chairman and Chief Executive Officer, is scheduled to present an ... Conference on Wednesday, September 9, 2009 at The Four Seasons Hotel in ... is scheduled for 9:30 a.m. ET. The presentation will be broadcast ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:Video: FDA States Consumers Should Continue to Use alli 2Health News:Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: